ProCE Banner Activity

Experts Answer HCP Questions on the Management of Myeloproliferative Neoplasms

Clinical Thought

In this commentary, experts address HCP questions on MPNs from a live webinar including treatment selection, novel therapeutics, and molecular testing.

Released: May 03, 2022

Expiration: May 02, 2023

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Stephen Oh

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
St Louis, Missouri

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Geron

Incyte Corporation

Sumitomo Dainippon Pharma ONC

Program Director Disclosure

Program Director

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has received consultant/advisor/speaker fees from AbbVie, Blueprint, Bristol Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, PharmaEssentia, and Sierra Oncology, and funds for research support from Astellas, Blueprint, Bristol Myers Squibb, Cogent, Constellation, CTI Biopharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.

Faculty Disclosure

Primary Author

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
St Louis, Missouri

Stephen Oh, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Blueprint, Bristol Myers Squibb, Constellation, CTI Biopharma, Disc Medicine, Geron, Incyte, PharmaEssentia, and Sierra Oncology.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has disclosed that he has received consulting fees from Constellation and PharmaEssentia.